期刊
AUTOIMMUNITY REVIEWS
卷 15, 期 10, 页码 1001-1004出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2016.07.020
关键词
Antiphospholipid syndrome; Anti-C1q antibody; Complement pathway; Antiphospholipid antibody
类别
资金
- JSPS KAKENHI grant [26293230, 25670455, 2564166]
- Grants-in-Aid for Scientific Research [16K09885, 25670455, 26293230] Funding Source: KAKEN
The involvement of complement activation in the pathophysiology of antiphospholipid syndrome (APS) was first reported in murine models of antiphospholipid antibody (aPL)-related pregnancy morbidities. We previously reported that complement activation is prevalent and may function as a source of procoagulant cell activation in the sera of APS patients. Recently, autoantibodies against C1q, a component of complement 1, were reported to be correlated with complement activation in systemic lupus erythematosus. These antibodies target neoepitopes of deformed C1q bound to various molecules (i.e., anionic phospholipids) and induce accelerated complement activation. We found that anti-C1q antibodies are more frequently detected in primary APS patients than in control patients and in refractory APS patients with repeated thrombotic events. The titer of anti-C1q antibodies was significantly higher in refractory APS patients than in APS patients without flare. The binding of C1q to anionic phospholipids may be associated with the surge in complement activation in patients with anti-C1q antibodies when triggered by 'second-hit' biological stressors such as infection. Such stressors will induce overexpression of anionic phospholipids, with subsequent increases in deformed C1q that is targeted by anti-C1q antibodies. (C) 2016 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据